Previous 10 | Next 10 |
– First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine Approved in Europe in Almost Two Decades for Indicated Patients – – NILEMDO Is Approved for Patients Who Require Additional LDL-Cholesterol Lowering on a Background Statin, Other Lipid-Low...
Apellis Pharmaceuticals (NASDAQ: APLS ) initiated with Strong Buy rating and $86 (221% upside) price target at Raymond James. More news on: Apellis Pharmaceuticals, Inc., BioXcel Therapeutics, Inc., Eidos Therapeutics, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
– First Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine in the U.S. in Nearly 20 Years for Indicated Patients Awaiting a New Option – – Esperion Aims to Set New Industry Standard by Pricing NEXLETOL for Patient Affordability and Access – ...
ANN ARBOR, Mich., March 28, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that two pooled analyses from four Phase 3 clinical trials of NEXLETOL and results from the Phase 2 (1002-058) study of NEXLIZET were presented at the American College of Cardiology’s 69 th S...
ANN ARBOR, Mich., March 23, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that two pooled analyses from four Phase 3 clinical trials of NEXLETOL and results from the Phase 2 (1002-058) study of NEXLIZET will be presented at the American College of Cardiology’s 69 th...
ANN ARBOR, Mich., March 18, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Alan Fuhrman as a Class III director, with a term expiring at the 2022 meeting of stockholders. "On behalf of the Lipid Management team and our directors, I am very pleased to ...
Arrowhead Pharmaceuticals (NASDAQ: ARWR ) initiated with Neutral rating and $45 (107% upside) price target at Goldman Sachs. More news on: Arrowhead Pharmaceuticals, Inc., Ocular Therapeutix, Inc., Blueprint Medicines Corporation, Healthcare stocks news, Stocks on the move, , Read more...
The following slide deck was published by Esperion Therapeutics, Inc. in conjunction with their 2019 Q4 earnings Read more ...
Anaplan (NYSE: PLAN ) -29% despite Q4 beat . More news on: Anaplan, Inc., Continental Resources, Inc., Nutanix, Inc., Stocks on the move, , Read more ...
Esperion Therapeutics ( ESPR ) Q4 results : Revenues: $1M. More news on: Esperion Therapeutics, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Esperion Therapeutics Inc. Company Name:
ESPR Stock Symbol:
NASDAQ Market:
Esperion Therapeutics Inc. Website:
ANN ARBOR, Mich., July 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2024 financial results before the market opens on Monday, August 12, 2024. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financi...
ANN ARBOR, Mich., July 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the BTIG Biotech Conference on Monday, August 5, 2024, at 4 p.m. ET. Esperion Therapeutics At Esperion, we discover, develop, and commercialize innovat...
– Targeted Campaign Reaches Patients at Risk for Heart Attack or Heart Procedures Because of High LDL Cholesterol (LDL-C) – – Animated Characters Are a Visual Representation of An Unseen Risk “Lurking” In Patients’ Artery Walls &...